These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35147696)

  • 41. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
    Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
    Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
    Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
    BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
    Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
    Diabetes Obes Metab; 2018 Dec; 20(12):2792-2799. PubMed ID: 29971914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
    Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
    Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
    Alkabbani W; Gamble JM
    Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study.
    Wu CY; Iskander C; Wang C; Xiong LY; Shah BR; Edwards JD; Kapral MK; Herrmann N; Lanctôt KL; Masellis M; Swartz RH; Cogo-Moreira H; MacIntosh BJ; Rabin JS; Black SE; Saskin R; Swardfager W
    Diabetes Care; 2023 Feb; 46(2):297-304. PubMed ID: 36508692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study.
    Ng PY; Ng AK; Ip A; Wu MZ; Guo R; Yiu KH
    Crit Care Med; 2023 Aug; 51(8):1074-1085. PubMed ID: 37026864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
    Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
    Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
    Alkabbani W; Shah BR; Zongo A; Eurich DT; Alsabbagh MW; Gamble JM
    Diabetes Obes Metab; 2023 Dec; 25(12):3490-3500. PubMed ID: 37563767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
    BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
    J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
    Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
    Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
    Shin A; Koo BK; Lee JY; Kang EH
    BMJ; 2024 Aug; 386():e079475. PubMed ID: 39197881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis.
    Al-Hindi B; Mohammed MA; Mangantig E; Martini ND
    J Am Pharm Assoc (2003); 2024; 64(1):9-26.e6. PubMed ID: 37844733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea.
    Kim K; Choi SH
    Diabetes Metab J; 2021 Jul; 45(4):502-504. PubMed ID: 34352987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.